Semaglutide Pill
Delivered every 23 days. Cancel anytime.
$76.00
every 23 days
$76.00
$399.00
one-time purchase
About This Product
What's Included
- ✓ Semaglutide Sublingual RDT (Rapid Dissolving Tablets), 1.5mg–9.3mg — 4 tablets per homekit
- ✓ Telehealth Access
Strength varies from 1.5mg to 9.3mg and is dependent on the month ordered.
Procedure
Place one rapid-dissolving tablet under the tongue and allow it to fully dissolve. Do not chew or swallow the tablet whole, and avoid eating or drinking while it dissolves. Instructional tutorial provided after purchase.
Purpose
Semaglutide Sublingual RDT is a needle-free, once-a-week option that works by mimicking hormones that target areas of the brain involved in regulating appetite and food intake. This can help you eat less and support weight loss.
Dosing Schedule
Once a week — taken on the same day each week. Detailed dosing schedule will be provided with the homekit.
*Each homekit ordered contains 4 tablets (1 month supply)
Diet and Exercise
Healthy eating and activity are recommended.
Benefits
- Weight Loss
- May improve Blood Pressure
- May improve Cholesterol
- Improves Blood Sugar
Most Common Side Effect
Nausea
Recommendations to limit Nausea: Eat bland, low-fat foods, like crackers, toast and rice. Eat foods that contain water, like soup and gelatin. Avoid laying down after eating. Eat slowly. Go outdoors for fresh air.
Physician Consent for Treatment: A physician may contact you within 24 hours of purchase if additional information is needed.
Important — Titration Schedule
This product follows a titration schedule. All patients must start with the Month 1 dose. After Month 1, the strength increases gradually in Month 2, 3, and 4. The maintenance dose can be ongoing for up to 8 months depending on your goals.
A minimum BMI of 27 or greater is required to order this product.
Shipping
This product requires refrigeration. It will be shipped 2-Day or Overnight with appropriate cold-chain packaging. Please refrigerate immediately upon receipt.
The Science Behind Semaglutide
What is Semaglutide?
Semaglutide is an incretin mimetic — specifically, a GLP-1 receptor agonist with 94% sequence homology to human GLP-1. Semaglutide binds and activates the GLP-1 receptor. GLP-1 is an important, gut-derived, glucose homeostasis regulator that is released after the oral ingestion of carbohydrates or fats.
In patients with Type 2 diabetes, GLP-1 concentrations are decreased in response to an oral glucose load. GLP-1 enhances insulin secretion, increases glucose-dependent insulin synthesis, suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation; semaglutide is stabilized against degradation by the DPP-4 enzyme.
Semaglutide reduces blood glucose by stimulating insulin secretion and lowering glucagon secretion — both in a glucose-dependent manner. When blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism also involves a minor delay in gastric emptying in the early postprandial phase.
Note: The clinical trial data referenced below were generated using FDA-approved subcutaneous (injectable) semaglutide. The safety and efficacy of compounded sublingual semaglutide have not been established in clinical trials, and bioavailability may differ from the injectable formulation. Individual results may vary.
References
This compounded medication contains Semaglutide formulated as a sublingual rapid-dissolving tablet for individual patients who may not tolerate standard formulations or who require a customized therapeutic approach. It is prepared in accordance with Section 503A of the Federal Food, Drug, and Cosmetic Act and dispensed solely pursuant to a valid patient-specific prescription from a licensed healthcare provider.
Our compounded formulation is not affiliated with, endorsed by, or intended to replace any FDA-approved semaglutide product. Compounded sublingual semaglutide is not an FDA-approved route of administration, and its safety, efficacy, and bioavailability have not been established in clinical trials.
This medication is not made for resale, bulk distribution, or office use, and is compounded exclusively to meet the clinical needs of individual patients when commercially available alternatives are not appropriate.